Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Introduction Since 2007, many countries have implemented national human papillomavirus
(HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been …

Background. Human papillomavirus (HPV) vaccination targeting females aged 12–13 years
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …

Genital warts (GWs) are common, with about 5% to 10% of people having at least one
episode in their lifetime. They develop about 2–3 months after infection with human …

Background The incidence of anogenital warts (AGW) decreased after the introduction of the
quadrivalent human papillomavirus (qHPV) vaccine in multiple jurisdictions. We studied how …

Introduction Vaccine effectiveness and impact studies are typically observational, generating
evidence after vaccine launch in a real-world setting. For human papillomavirus (HPV) …

Background. When the bivalent and the quadrivalent HPV vaccines were marketed they
were presented as having comparable efficacy against cervical cancer. Differences between …

In Australia, school-based human papillomavirus (HPV) vaccination was introduced initially
for girls in 2007, and then also for boys in 2013. While studies have shown declines in the …

Background The quadrivalent human papillomavirus (HPV) vaccine was introduced in the
Portuguese National Immunization Program in October 2008, targeting 13-year-old girls …

IMPORTANCE: The majority of literature related to disparities in human papillomavirus
(HPV) vaccination has been focused on sociodemographic differences in vaccine uptake …